A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC

Conditions: Metastatic Castration-resistant Prostate Cancer Interventions: Drug: 177Lu-NYM032 injection Sponsors: Norroy Bioscience Co., LTD Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials